clinical trial · NCT07370909
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
Shanghai Longwood Biopharmaceuticals Co., Ltd.·phase3·not yet recruiting·n = 480
Moderate to Severe Atopic DermatitisLW402Placebo
brief summary
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
started
Jan 30, 2026
primary completion
Mar 31, 2028
completion
Dec 31, 2028
last updated
Jan 29, 2026
official title
A Multi-center, Randomized, Double Blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Moderate-to-severe Atopic Dermatitis.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol